People · Operator
Named in public records as an officer, director or promoter · active 2016–2019 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pliant Therapeutics, Inc. | — | Biotechnology | Series D+ | $162.6M | $4.1B | 2018 |
| Myoscience, Inc | — | Other | Series B | $122.6M | $83.1M | 2016 |
Bernard Coulie at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bernard Coulie on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Ferrari | 1 | 15 |
| Robert Grant | 1 | 12 |
| Hoyoung Huh | 1 | 7 |
| Anthony Lando | 1 | 6 |
| Brian Farley | 1 | 5 |
| NEIL EXTER | 1 | 5 |
| Richard M. Ferrari | 1 | 5 |
| Charles Homcy | 1 | 4 |
| Cary . Vance | 1 | 4 |
| Clint Carnell | 1 | 4 |
| Kevin Raidy | 1 | 4 |
| Gayle Crowell | 1 | 3 |
| Thomas E. Hancock | 1 | 3 |
| Jan Pensaert | 1 | 3 |
| Rudi Marien | 1 | 3 |
| Jon Serbousek | 1 | 3 |
| Thomas Weldon | 1 | 3 |
| Jeffrey M. Nugent | 1 | 2 |
| Robert M. Curtis | 1 | 2 |
| John Curnutte | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.